Moreover, a multicenter study conducted on the off-label use of TPO-RAs in pediatric patients noted two thrombotic events not associated with thrombocytosis in patients treated with eltrombopag with underlying risk factors for thrombosis (28). This evidence concerns the gene TPO and Thrombocytosis.